No Data
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
CureVac CVAC GSK Deal and Restructuring; Scilex SCLX Letter of Intent DECA
Express News | CureVac NV: UK Trial on Validity of Intellectual Property Rights Ep 3 708 668 B1 and Ep 4 023 755 B1 Began July 10; Judgement Expected Later in 2024
Express News | CureVac NV - New Trial Date for U.S. Patent Litigation Set for March 3, 2025, Following Settlement With Acuitas Therapeutics
CureVac: A Buy Rating Amidst Intellectual Property Litigation and Strong Valuation Metrics
CureVac Announced The Latest Trial Dates For Its Ongoing Patent Litigation Against Pfizer/BioNTech In Multiple Geographies, Including The U.S., UK, And Germany
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology)